Quest Diagnostics Inc (DGX)
NYSE · Price as of · Delayed Quote
- Analysts15
- Implied upside+7.2%
- Target range$204.00 to $265.00
- EPS expected$2.86 +10%
- A year ago$2.60
- Revenue expected$3.05B +8.2%
- Estimate range$2.82 to $2.91
Congress trades in DGX
| Date | Member | Action | Amount | |
|---|---|---|---|---|
| 2026-03-27 | Alan Armstrong OK | Purchase | $1,001 - $15,000 | |
| 2025-10-30 | Julie Johnson TX | Sale | $1,001 - $15,000 | |
| 2025-10-30 | Julie Johnson TX | Purchase | $1,001 - $15,000 | |
| 2025-03-10 | Carol Devine Miller WV | Sale | $15,001 - $50,000 |
SEC filings
Frequently asked questions
When does DGX report earnings?
Quest Diagnostics Inc (DGX) is scheduled to report quarterly results on October 22, 2026, before the open. The 13-analyst consensus is $2.86 per share on revenue of $3.05B for the quarter ended September 30, 2026, against $2.60 and $2.82B a year earlier. It has beaten the consensus EPS estimate in all four of the last four quarters.
What do analysts expect for DGX?
15 analysts cover Quest Diagnostics Inc (DGX). The consensus rating is Buy. The average price target is $247.73, in a range of $204.00 to $265.00.
Are insiders buying or selling DGX?
We have no qualifying Form 4 insider purchases or sales on record for Quest Diagnostics Inc (DGX). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Where can I see DGX SEC filings?
We could not resolve current EDGAR filings for DGX. This usually means the ticker is a foreign or over-the-counter listing that does not file with the SEC.